Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 120

Showing 26-50 of 120 citing articles:

Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells
Mengdie Hu, Xiaomei Li, Lin Wang, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 3, pp. 406-412
Closed Access | Times Cited: 5
Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design
Yu Chen, Fengyuan Liu, Samira Pal, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 19, pp. 9582-9608
Closed Access | Times Cited: 5
Mechanism of degrader-targeted protein ubiquitinability
Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, et al.
Science Advances (2024) Vol. 10, Iss. 41
Open Access | Times Cited: 5
Auto-RapTAC: A Versatile and Sustainable Platform for the Automated Rapid Synthesis and Evaluation of PROTAC
Jiexuan Chen, Mingfei Wu, Jun Mo, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Selective degradation of BRD9 by a DCAF16-recruiting targeted glue: mode of action elucidation and in vivo proof of concept
Scott J. Hughes, Wojciech J. Stec, Colin Davies, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Factors to Consider for Synthesis in 1536-Well Plates─An Amide Coupling Case Study for PROTAC Synthesis
Rebecca Stevens, Harry E. P. Palmer, Afjal H. Miah, et al.
The Journal of Organic Chemistry (2025)
Open Access
A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins
Ishaar P. Ganesan, Hiroaki Kiyokawa
Cancers (2025) Vol. 17, Iss. 4, pp. 626-626
Open Access
Recent advances in targeted degradation in the RAS pathway
Zhiming Ge, Zisheng Fan, Wei He, et al.
Future Medicinal Chemistry (2025), pp. 1-16
Closed Access
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang, Chunchu Deng
Molecular Neurobiology (2025)
Open Access
Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer
Meghri Katerji, K. Bergman, Eric Lindberg, et al.
Journal of Biological Chemistry (2025), pp. 108452-108452
Open Access
Recent advances in PROTAC-based antiviral and antibacterial therapeutics
Can Zhou, Shiwei Yang, Jun Wang, et al.
Bioorganic Chemistry (2025), pp. 108437-108437
Closed Access
Switchable and Stereospecific C-Glycosylation Strategy via Formal Functional Group Deletion
Xiaoshen Ma, Stephen J. Sujansky
The Journal of Organic Chemistry (2025)
Closed Access
Design and characterization of a heterobifunctional degrader of KEAP1
Hao Chen, Nghi Nguyen, Charlene M. Magtoto, et al.
Redox Biology (2022) Vol. 59, pp. 102552-102552
Open Access | Times Cited: 20
Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α
Monica Cubillos‐Rojas, Guillem Loren, Yusuf Zaim Hakim, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 611-611
Open Access | Times Cited: 11
Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression
Wei Wang, Youwei Li, Liu Tang, et al.
Cancer Letters (2024) Vol. 591, pp. 216849-216849
Open Access | Times Cited: 4
Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability
Hao Wu, Jeremy Murray, Noriko Ishisoko, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8585-8608
Closed Access | Times Cited: 4
A patent review on hypoxia-inducible factor (HIF) modulators (2021–2023)
Jia‐Ming Liu, Yinli Gao, Xiaojin Zhang
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 651-664
Closed Access | Times Cited: 4
Ubiquitin recruiting chimera: more than just a PROTAC
Tatyana A. Grigoreva, Daria Novikova, Gerry Melino, et al.
Biology Direct (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 4
Discovery of novel benzosultam CRBN ligands
Hoyeong Park, Santosh Shivanand Raikar, Yonghyo Kim, et al.
Bulletin of the Korean Chemical Society (2025)
Closed Access
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Lisha Ou, Mekedlawit Setegne, Jeandele Elliot, et al.
Chemical Reviews (2025)
Closed Access
PI5P4K inhibitors: promising opportunities and challenges
Koh Takeuchi, Lisa Nagase, Shun Kageyama, et al.
FEBS Journal (2025)
Open Access
A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)
Aina Urbina, Alex J. Hallatt, Jack Robertson, et al.
Expert Opinion on Therapeutic Patents (2025), pp. 1-42
Closed Access
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access

Scroll to top